Morel, Thomas Fournier, Jean-Pascal
Polypharmacy is associate with serious drug event as hospitalizations or falls. Prescribingcascades contribute to polypharmacy by increasing the burden of inappropriate medications.A prescribing cascade occur when a drug is prescribed to treat an unrecognized adversedrug event caused by a previously prescribed drug. Nine clinically important prescr...
Kishk, Omayma A Kim, Ivone Cheng, Carmen Summan, Mukesh Muñoz, Monica A
Published in
Pediatric nephrology (Berlin, Germany)
The objective of this report is to identify and characterize cases of fibrosing colonopathy, a rare and underrecognized adverse event, associated with cysteamine delayed-release (DR) in patients with nephropathic cystinosis. We searched the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the medical literature for postm...
Chabanne, Luc Cervone, Mario
La vaccination n'augmente pas le risque d'anémie immunologique chez le chien, même si elle doit être prise en compte lors du diagnostic de ce type d'affection. La mise en place d'un traitement immunosuppresseur implique une adaptation du calendrier et des protocoles vaccinaux. Il est recommandé de mettre à jour les vaccinations avant le début du tr...
Wu, Junlin Wu, Hanbiao Chen, Lili Liang, Haiping Huang, Guoning Yang, Sensen Chen, Bishan Noguchi, Yoshihiro Shen, Yonggang
Published in
Expert opinion on drug safety
Daratumumab is widely used in multiple myeloma (MM) and light chain amyloidosis (AL amyloidosis). The purpose of this study was to identify adverse event (AE) signals for daratumumab through the FDA Adverse Event Reporting System (FAERS) database to assess its safety in a large sample of people. Based on data from the FAERS database, three dispropo...
Liu, Yuan Xu, Xiaoli Yang, Jingfei Zhang, Yuwei He, Mengjiao Liao, Wenzhi Wang, Na Liu, Pengcheng
Published in
Expert opinion on drug safety
This study aimed to adopt the conventional signal detection methods to explore a new way of risk identification and to mine important drug risks from the perspective of big data based on Zhenjiang Adverse Event Reporting System (ZAERS). Data were extracted from ZAERS database between 2012 and 2022. The risks of all the reported drug event combinati...
Simão, Letícia Demetrio
TCC (graduação) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Farmácia. / A farmacovigilância monitora a segurança dos medicamentos após a comercialização. Este campo ganhou relevância após o desastre da Talidomida em 1961, que levou à criação do Programa Internacional de Monitorização de Medicamentos pela Organização Mundi...
Boléa, Emmanuelle
Les effets indésirables et les événements indésirables graves liés aux soins (EIGS) constituent deux facteurs majeurs d’hospitalisation ou de prolongation d’hospitalisation pouvant conduire au décès. Il est crucial de les prévenir. Le pharmacien, en raison de sa proximité avec les usagers et de son implication dans le circuit du médicament, doit êt...
Baptista, Trino Motuca, Mariano Serrano, Ana Perez Lo Presti, Alirio Fernandez-Arana, Alberto Olmos, Ismael Pabon, Albis Yepez, Juan Genaro Ayala Alejo Galarza, Gabriel de Jesus Rivera Ramirez, Nuria Monserrat
...
Published in
Schizophrenia research
There is growing interest in clozapine clinical use, monitoring, and research, particularly adverse drug reactions (ADRs) other than agranulocytosis. In this study we focused on clozapine pharmacovigilance. Hence, we contacted clinicians and researchers in Latin America and requested information about local psychiatric services, clozapine availabil...
Schulte, Peter F J Veerman, Selene R T Bakker, Bert Bogers, Jan P A M Jongkind, Amy Cohen, Dan
Published in
Schizophrenia research
After the introduction of clozapine eight Finnish patients died after developing agranulocytosis. Clozapine was withdrawn from the market and only reintroduced with strict mandatory white blood cell monitoring as long as treatment lasts and thresholds at which clozapine must be discontinued definitively. The fear of agranulocytosis and the need for...
Alj, Loubna Mamadou, Prof Baldé, Aliou
La pharmacovigilance a pour but la sécurité des patients. Ce guide oriente le processus de pharmacovigilance au sein du CHU.Il explique clairement le rôle de chaque acteur qui devrait être impliqué dans le processus de pharmacovigilance. Ce guide a été élaboré pour faciliter la décentralisation de la pharmacovigilance au sein du CHU. Il répond au b...